DGCI Gives Green Signal To Itolizumab Drug For Pandemic Treatment

Sat Jul 11 2020 17:05:21 GMT+0530 (IST)

In the light of the situation in India reached an alarming level, drug regulator, Drug Controller General of India(DCGI) gave its nod to use Itolizumab drug for the pandemic patients.

Though DCGI approved Itolizumab drug to treat the patients, the drug should be used only, under "restricted emergency use for patients who develop moderate to severe symptoms of the virus.

The Drug is mainly used for curing skin ailment psoriasis. It is believed that the drug has the ability to bring down the self-damaging response of the immune system in the body.

The ongoing pandemic works in a way that the virus gets multiped and progresses in the body which in turn results in the immune system overreacting. This condition makes the body vulnerable to the virus.

The Biocon drug Itolizumab which already got approves is raising many hopes and the drug helps in calming down the overreacting immune system and going by this, the DGCI allowed the drug to use the drug for only moderate to severe patients.

One vial of the drug will be costing around Rs 7,950 and as per the instructions, four vials will be enough for a patient. Full Course will be costing around Rs 32,000